Antengene Pipeline Overview - Antengene is developing a diverse pipeline of Antibody Drug Conjugates (ADCs), Immuno-Oncology (IO) therapies, and treatments for Autoimmune Diseases [16, 102] - The company's "2+1" T Cell Engager (TCE) platform, AnTenGager, is designed with steric hindrance-masking technology to enhance therapeutic effect and safety [20, 109] ATG-022 (Claudin 18.2 ADC) - ATG-022, a Claudin 18.2 ADC, has shown efficacy across various CLDN18.2 expression levels in gastric cancer [20, 32, 48] - In CLDN18.2 moderate to high expressing GC (IHC 2+ > 20%) patients treated with ATG-022 at 2.4 mg/kg, the ORR was 40% (12/30), and the DCR was 90% (27/30) [20] - In CLDN18.2 low and ultra-low expressing GC (IHC 2+ ≤ 20%) patients, an efficacious dose range of 1.8-2.4 mg/kg of ATG-022 resulted in an ORR of 33.3% (6/18) and a DCR of 50% (9/18) [20] - The median progression-free survival (mPFS) in Gastric or GEJ Cancer with Moderate to High CLDN18 2 Expression (IHC 2+, >20%) Treated at 2 4 mg/kg is 6 97 months, with a 6-month progression-free survival (PFS6m) rate of 51 1% [53] - The company is planning to investigate ATG-022 in combination with Pembrolizumab and CAPOX in Advanced / Metastatic Claudin 18 2 Positive Gastric Cancer (1L) [64] - ATG-022 is estimated to have over US$5 billion in peak sales potential [68, 70] ATG-037 (Oral CD73 Small Molecule Inhibitor) - ATG-037, an oral CD73 small molecule inhibitor, has demonstrated efficacy in CPI-resistant Melanoma with an ORR of 36.4% (4/11) and a DCR of 100% (11/11) [20] - In CPI-resistant Non-small Cell Lung Cancer, ATG-037 showed an ORR of 21.4% (3/14) and a DCR of 71.4% (10/14) [20] - The Immuno-oncology (IO) market is estimated to be $140+ billion in 2028 [78] AnTenGager TCE Platform - ATG-201, a CD19 x CD3 TCE, is IND-enabling for B Cell Driven Autoimmune Diseases, demonstrating deep B cell depletion with low CRS [16, 20, 119] - ATG-106 (CDH6 x CD3) is a First-in-Class CDH6 TCE for Ovarian Cancer and Kidney Cancer [17, 103, 132]